(Q36842715)

16 August 2017

1 reference

title

Her signaling in pancreatic cancer (English)

1 reference

16 August 2017

1 reference

Barbara Burtness

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

823-829

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.6.823

21 January 2018

Identifiers

DOI

10.1517/14712598.7.6.823

1 reference

release_vbaijdbnk5b3papgzeko3yjtle

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vbaijdbnk5b3papgzeko3yjtle

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference